Market Cap 162.34B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.69
Forward PE 9.45
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 30,920,600
Avg Vol 44,932,004
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 82%
Beta 0.43
Analysts Sell
Price Target $28.98

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
DragonAlgo
DragonAlgo Apr. 3 at 10:05 PM
šŸ‰ $PFE CALL — DragonAlgoĀ® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $28.50 | Type: CALL Option Plan (premium): Entry: $0.31 Stop: $0.22 TP1: $0.40 TP2: $0.53 TP3: $0.74 šŸ”— https://dragonalgo.com
0 Ā· Reply
DrSilbergleit
DrSilbergleit Apr. 3 at 8:03 PM
$SPY $QQQ $XLE $USO $PFE ā€œWe are watching a superpower developing super scientific capabilities, and our whole effort is how to slow [China] down, rather than how to become better than them,ā€ says Albert Bourla, chairman and CEO of Pfizer, Inc. ā€œThe only way to be able not to lose the edge that we have—it is if we do changes inside our American ecosystem of biotech, of science, of academia, of pharmaceuticals, of capital markets, venture capital.ā€
0 Ā· Reply
GlobalTeamAlerts
GlobalTeamAlerts Apr. 3 at 5:01 PM
$PFE pharmaceutical giant Pfizer.
0 Ā· Reply
PickAlpha
PickAlpha Apr. 3 at 3:38 PM
PickAlpha Morning Report - Macro Events: 2026.04.03 Event Analysis - 1/4: Trump orders new pharmaceutical tariffs and resets metals-derivative duties, creating immediate pricing and supply-chain implications for pharma, metals, industrials and power-grid equipment | View: Policy shock alters competitive dynamics for pharmaceuticals and metals… $PFE $REGN $SLX $CPER
0 Ā· Reply
topstockalerts
topstockalerts Apr. 3 at 3:04 PM
Trump Tariffs: One-Year Impact A year after Trump’s tariffs, U.S. companies are adjusting supply chains and absorbing costs amid changing policies (reciprocal tariffs struck down; global 10–15% tariffs; Section 232 on steel/aluminum). Retail: Large chains managed; smaller firms struggled. Price increases passed to consumers in some cases. Examples: Walmart, Home Depot, Abercrombie & Fitch, American Eagle, Gap, Dollar Tree. Automotive: Billions in tariffs absorbed; supply chains shifted and U.S. production increased. Examples: GM, Ford, Stellantis, Toyota, Nissan, Honda. CPG: Costs rose for imported materials; mitigated via pricing, sourcing changes, or absorbed. Examples: Procter & Gamble, McCormick, Constellation Brands, J.M. Smucker. Pharma: Price agreements and tariffs incentivized domestic manufacturing. Examples: Pfizer, Eli Lilly, Merck, Gilead, Bristol Myers, Novo Nordisk, GSK, Novartis, AbbVie, Johnson & Johnson. $WMT $HD $GM $PFE $LLY
0 Ā· Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien šŸ‘½ šŸ‘¾ https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 Ā· Reply
CapitalSignalWorks
CapitalSignalWorks Apr. 3 at 2:34 PM
Big shift happening in pharma M&A right now… The race for T-cell engager therapies is heating up fast. These next-gen bispecific antibodies are redefining cancer treatment—and big players aren’t sitting on the sidelines. $AMGN and $PFE are активно moving in, snapping up innovative biotech platforms to lock in leadership in this high-growth space. The message is clear: whoever controls T-cell engager tech could dominate the future of oncology. This isn’t just a trend—it’s a strategic land grab in one of the most promising areas of modern medicine. Watch the deal flow… because the next acquisition could be a game-changer.
0 Ā· Reply
CapitalismUSA
CapitalismUSA Apr. 3 at 12:35 PM
$PFE Pfizer investors…I hope you are aware of the multi billion patent infringement lawsuit that will be going against you! If you don’t believe me, just ask Moderna.
0 Ā· Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 3 at 12:08 PM
$JNJ $UNH $PFE defensive names quietly holding up. not sexy, but money parks here when things get shaky
1 Ā· Reply
WunDumFuc
WunDumFuc Apr. 3 at 11:47 AM
0 Ā· Reply
Latest News on PFE
Pfizer: Why Wall Street Habitually Overestimates Target Price

Mar 27, 2026, 3:48 PM EDT - 7 days ago

Pfizer: Why Wall Street Habitually Overestimates Target Price


Why Pfizer Remains A Strong Buy In 2026

Mar 27, 2026, 10:46 AM EDT - 7 days ago

Why Pfizer Remains A Strong Buy In 2026


Pfizer: Time To Buy The Turnaround

Mar 25, 2026, 2:06 AM EDT - 9 days ago

Pfizer: Time To Buy The Turnaround


5 ā€˜Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 12 days ago

5 ā€˜Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH


Pfizer: I'm Still Expecting A Massive Rebound

Mar 18, 2026, 9:00 AM EDT - 16 days ago

Pfizer: I'm Still Expecting A Massive Rebound


China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 4 weeks ago

China approves Pfizer GLP-1 drug for weight management


Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar 4, 2026, 11:31 AM EST - 4 weeks ago

Seven S&P500 Ideal 'Safer' March Dividend Dogs

AMCR ARE BBY BEN BXP CAG CCI


Pfizer's Quiet Cash Comeback

Mar 3, 2026, 9:50 AM EST - 4 weeks ago

Pfizer's Quiet Cash Comeback


Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 4 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership


Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 5 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug


Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 5 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences


Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 5 weeks ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors


Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 6 weeks ago

Is There 25% Downside For Pfizer Stock?


Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 5:42 PM EST - 6 weeks ago

Pfizer: The Rebound Looks Unsustainable


DragonAlgo
DragonAlgo Apr. 3 at 10:05 PM
šŸ‰ $PFE CALL — DragonAlgoĀ® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $28.50 | Type: CALL Option Plan (premium): Entry: $0.31 Stop: $0.22 TP1: $0.40 TP2: $0.53 TP3: $0.74 šŸ”— https://dragonalgo.com
0 Ā· Reply
DrSilbergleit
DrSilbergleit Apr. 3 at 8:03 PM
$SPY $QQQ $XLE $USO $PFE ā€œWe are watching a superpower developing super scientific capabilities, and our whole effort is how to slow [China] down, rather than how to become better than them,ā€ says Albert Bourla, chairman and CEO of Pfizer, Inc. ā€œThe only way to be able not to lose the edge that we have—it is if we do changes inside our American ecosystem of biotech, of science, of academia, of pharmaceuticals, of capital markets, venture capital.ā€
0 Ā· Reply
GlobalTeamAlerts
GlobalTeamAlerts Apr. 3 at 5:01 PM
$PFE pharmaceutical giant Pfizer.
0 Ā· Reply
PickAlpha
PickAlpha Apr. 3 at 3:38 PM
PickAlpha Morning Report - Macro Events: 2026.04.03 Event Analysis - 1/4: Trump orders new pharmaceutical tariffs and resets metals-derivative duties, creating immediate pricing and supply-chain implications for pharma, metals, industrials and power-grid equipment | View: Policy shock alters competitive dynamics for pharmaceuticals and metals… $PFE $REGN $SLX $CPER
0 Ā· Reply
topstockalerts
topstockalerts Apr. 3 at 3:04 PM
Trump Tariffs: One-Year Impact A year after Trump’s tariffs, U.S. companies are adjusting supply chains and absorbing costs amid changing policies (reciprocal tariffs struck down; global 10–15% tariffs; Section 232 on steel/aluminum). Retail: Large chains managed; smaller firms struggled. Price increases passed to consumers in some cases. Examples: Walmart, Home Depot, Abercrombie & Fitch, American Eagle, Gap, Dollar Tree. Automotive: Billions in tariffs absorbed; supply chains shifted and U.S. production increased. Examples: GM, Ford, Stellantis, Toyota, Nissan, Honda. CPG: Costs rose for imported materials; mitigated via pricing, sourcing changes, or absorbed. Examples: Procter & Gamble, McCormick, Constellation Brands, J.M. Smucker. Pharma: Price agreements and tariffs incentivized domestic manufacturing. Examples: Pfizer, Eli Lilly, Merck, Gilead, Bristol Myers, Novo Nordisk, GSK, Novartis, AbbVie, Johnson & Johnson. $WMT $HD $GM $PFE $LLY
0 Ā· Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien šŸ‘½ šŸ‘¾ https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 Ā· Reply
CapitalSignalWorks
CapitalSignalWorks Apr. 3 at 2:34 PM
Big shift happening in pharma M&A right now… The race for T-cell engager therapies is heating up fast. These next-gen bispecific antibodies are redefining cancer treatment—and big players aren’t sitting on the sidelines. $AMGN and $PFE are активно moving in, snapping up innovative biotech platforms to lock in leadership in this high-growth space. The message is clear: whoever controls T-cell engager tech could dominate the future of oncology. This isn’t just a trend—it’s a strategic land grab in one of the most promising areas of modern medicine. Watch the deal flow… because the next acquisition could be a game-changer.
0 Ā· Reply
CapitalismUSA
CapitalismUSA Apr. 3 at 12:35 PM
$PFE Pfizer investors…I hope you are aware of the multi billion patent infringement lawsuit that will be going against you! If you don’t believe me, just ask Moderna.
0 Ā· Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 3 at 12:08 PM
$JNJ $UNH $PFE defensive names quietly holding up. not sexy, but money parks here when things get shaky
1 Ā· Reply
WunDumFuc
WunDumFuc Apr. 3 at 11:47 AM
0 Ā· Reply
ericmarcellus
ericmarcellus Apr. 3 at 11:28 AM
A 100% tariff on patented drugs would be a major shock to the pharma cost structure Big names under pressure: • $PFE ($28.24, -0.95%) • $MRK ($120.22, +0.01%) → Potential margin compression as costs rise and pricing flexibility tightens Potential beneficiaries: • Generics like $TEVA could capture share as buyers look for cheaper alternatives Broader market impact: • Healthcare ETF $XLV ($146.71, -0.62%) may see increased volatility as the sector reprices risk • Could accelerate a shift in manufacturing toward lower-cost regions • Might even force a new wave of biotech innovation to offset cost pressures This isn’t just a headline — it’s a structural change that could reshape pharma economics if it sticks.
0 Ā· Reply
kristianwx90
kristianwx90 Apr. 3 at 9:26 AM
$PFE flat with pressure
0 Ā· Reply
DragonAlgo
DragonAlgo Apr. 3 at 7:12 AM
šŸ‰ $PFE CALL — DragonAlgoĀ® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $28.50 | Type: CALL Option Plan (premium): Entry: $0.31 Stop: $0.22 TP1: $0.40 TP2: $0.53 TP3: $0.74 šŸ”— https://dragonalgo.com
0 Ā· Reply
MorganHoratio
MorganHoratio Apr. 3 at 7:07 AM
The spouse of Susan Collins just picked up corporate bonds from Pfizer ($PFE). Here’s why that matters Bond buyers care about stability, cash flow, and downside protection — not hype. This kind of move suggests: Confidence in Pfizer’s ability to service debt Lower perceived default risk Preference for income + safety over equity upside Translation: this isn’t a ā€œmoonshotā€ signal… it’s a defensive confidence play. In a market full of uncertainty, smart money sometimes whispers instead of shouts. Worth watching how $PFE equity reacts from here.
1 Ā· Reply
BigBreakingWire
BigBreakingWire Apr. 3 at 5:00 AM
US to impose up to 100% tariffs on patented pharma and APIs from July 31, 2026; 20% for onshoring firms rising to 100% by 2030. 53% drugs imported, only 15% APIs domestic; generics exempt. Read šŸ‘‡ https://bigbreakingwire.in/us-imposes-100-tariffs-on-pharma-imports/ $SPY $QQQ $NIFTY50.NSE $PFE $SUNPHARMA.NSE
0 Ā· Reply
DirectHubTeam
DirectHubTeam Apr. 3 at 4:16 AM
$PFE pharmaceutical giant Pfizer.
0 Ā· Reply
MarcoRossi
MarcoRossi Apr. 3 at 12:58 AM
$PFE Manufacture: Made in USA USA. As an American company with 175 years of history, we are proud to be world leaders in medical innovation. Our supply, manufacturing and distribution facilities in the US. U.S. focus on ensuring that all Pfizer products are made to the highest standards of quality, safety and effectiveness
0 Ā· Reply
Judykay
Judykay Apr. 2 at 8:38 PM
$PFE Come join us $KODK
0 Ā· Reply
markbrogan
markbrogan Apr. 2 at 8:15 PM
$PFE Pfizer is an American company. Why are people posting about tariffs for Pfizer?
1 Ā· Reply
Typecheck
Typecheck Apr. 2 at 8:08 PM
$PFE Darn. Looks like it hit a wall.
0 Ā· Reply
Micheal_Pothead
Micheal_Pothead Apr. 2 at 8:01 PM
$PFE no way it closed 1 cent under my average
1 Ā· Reply
FrankieSmilez
FrankieSmilez Apr. 2 at 7:38 PM
BREAKING: Trump to impose 100% TARIFF on patented drugd and 25% TARIFF on Copper, Aluminum and steel derivatives $TSLA $NVDA $SPY $UNH $PFE
2 Ā· Reply